1 / 10

22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60

22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director. The global burden of tuberculosis. A third of the global population i.e. over 2 billion people are infected with the organism that causes TB

wattan
Télécharger la présentation

22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director

  2. The global burden of tuberculosis • A third of the global population i.e. over 2 billion people are infected with the organism that causes TB • 10% of the infected individuals eventually develop TB disease in their lifetime with around 9.5 million news cases and 2 million deaths occurring each year • Drug resistance and HIV adds to the burden • Lack of effective and adequate tools for diagnosis, treatment and prevention of the disease exacerbates the problem

  3. Working in partnerships through EDCTP • Coordination of national programmes • Partnerships with high- burdened countries • Capacity development and networking • Synergy among R&D international partners EDCTP

  4. The EDCTP partnership EDCTP-EEIG member states • Austria • Belgium • Denmark • France • Germany • Greece • Ireland • Italy • Luxembourg • Netherlands • Norway • Portugal • Spain • Sweden • Switzerland • United Kingdom Sub-Saharan African countries • Benin • Botswana • Burkina Faso • Cameroon • Congo • Cote d’Ivoire • Democratic Republic of Congo • Ethiopia • Gabon • Ghana • Guinea • Guinea-Bissau • Guinea-Conakry • Kenya • Liberia • Madagascar • Malawi • Mali • Mozambique • Namibia • Nigeria • Rwanda • Senegal • South Africa • Sudan • Tanzania • The Gambia • Togo • Uganda • Zambia • Zimbabwe

  5. TB diagnostics and biomarkers • Simple, accurate and efficient tools for diagnosing TB, especially at the point of care are lacking • Diagnosis in children and HIV-infected individuals is problematic • Vaccine studies are handicapped by the lack of correlates of immune protection • There is therefore an urgent need to invest in research on new diagnostics and biomarkers that will help us to accurately diagnose TB and understand better immunity against the disease

  6. Vaccines development • BCG – the current vaccine in use since 1921 is far from ideal • Newer vaccines are emerging along the pipeline with EDCTP through North-South partnerships funding several phase II clinical trials of some of them • There is a need to rationally plan phase III trials in terms of the clinical trials designs and funding

  7. TB treatment • The current TB treatment regimens require long periods from start to cure and are cumbersome requiring patients to take many pills • This often results in poor adherence to treatment, which in turn encourages drug resistance

  8. TB treatment clinical trials • Drug sensitive TB • Shortening and simplification of the current treatment regimens (The Pan-African Consortium for Evaluation of Anti-tuberculosis Antibiotics – PanACEA): 11 African, 10 European institutions + Global TB Alliance, Sequella, Bayer, BMGF • HIV/TB co-infection • Treatment optimisation • Safety profiling • Drug resistant TB • Nearly 0.5 million cases world-wide (China, India, Russian Federation contributing 50% of the cases)

  9. Capacity development and networking • National Regulatory Authorities and Ethics Review Committees support • Personnel training (Long- and short-term) • Research infrastructure support • Clinical trial sites upgrade • Laboratory improvements/accreditation • Policy, governance and health systems strengthening

  10. Thank you http://www.edctp.org

More Related